Study on the application of remazolam in painless bronchoscopy

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200065977

Enrollment

Unknown

Registered

2022-11-21

Start date

2022-12-01

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients undergoing bronchoscopy

Interventions

R1 group:Remazolam 0.15 mg/kg

R2 group:Remazolam 0.20 mg/kg

R3 group:Remazolam 0.25 mg/kg

Group P:Propofol 2 mg/kg

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. A total of 120 patients, who underwent fiberoptic bronchoscopy in the Fifth Affiliated Hospital of Southern Medical University from September 2022 to August 2024 were selected; 2. ASA grade I-II, aged 18-70 years; 3. All patients voluntarily participated in this study, and all participants signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Complicated with severe arrhythmia; 2. There is vital organ insufficiency; 3. The presence of neurological diseases; 4. A history of drug allergy.

Design outcomes

Primary

Measure	Time frame
Calm effect;Cognitive function;	—

Secondary

Measure	Time frame
Vital signs;Adverse reactions;	—

Countries

China

Contacts

Public ContactHe Liang

The Fifth Affiliated Hospital of Southern Medical University

54061799@qq.com+86 18928961518

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026